On January 19th, Imeik Technology Development Co.,Ltd. responded to investor inquiries on an interactive platform, stating that the company has established a comprehensive product line. This portfolio includes a series of sodium hyaluronate-based dermal fillers, polylactic acid-based dermal fillers, poly-p-dioxanone facial threads, and biological preparations based on neuro-modulating botulinum toxin. The company leverages its all-encompassing and differentiated product matrix to satisfy the diverse and multifaceted needs of its users.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments